Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...
“Gilead’s restrictions on access to lenacapavir could allow the HIV epidemic to spread. This is the closest we have ever been ...
Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...
Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...
Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...
The New Republic on MSN5dOpinion
Big Pharma Is the Only Reason Anyone Still Dies From HIVWhile antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...
On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...
The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and recently results published show it worked nearly as well in men.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback